Literature DB >> 7298981

Predicting recurrence of basal-cell carcinomas treated by microscopically controlled excision: a recurrence index score.

D S Rigel, P Robins, R J Friedman.   

Abstract

Despite the high cure rate achieved for basal-cell carcinomas treated with microscopically controlled excision, recurrences do occur. To determine if lesions that are likely to recur may be predicted at the time of surgery, data from 5020 patients with 7010 basal-cell carcinomas treated with Mohs' technique were reviewed. Two thousand nine hundred sixty (2960) lesions with five-year follow-up were studied (overall recurrence rate = 2.6%). Sex and age of the patients, size and location of lesions, types of previous therapy, and the number of surgical stages of microscopically controlled excision were all found to correlate significantly with recurrence rate (p less than 0.01). Multiple regression analysis was performed to determine the relative contribution of each of these variables to predictability of recurrences by a weighted scoring system. The derived model delineated the lesions into no-risk, low-, medium-, and high-risk groupings (p less than 0.000001). Lesions in the high-risk group had a recurrence rate of 10.1%, almost four times greater than the average. More aggressive microscopically controlled excisions and closer follow-up care are indicated for those lesions that can be predicted to result in a high-risk score.

Entities:  

Mesh:

Year:  1981        PMID: 7298981     DOI: 10.1111/j.1524-4725.1981.tb00171.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  2 in total

1.  [Basal cell carcinoma of the face and scalp : An update on treatment options].

Authors:  B Frerich; F Prall
Journal:  Pathologe       Date:  2018-09       Impact factor: 1.011

Review 2.  Surgical treatment of basal cell carcinoma: an algorithm based on the literature.

Authors:  Flávio Barbosa Luz; Camila Ferron; Gilberto Perez Cardoso
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.